2549-33-9

Basic information

• Product Name: 4-(ChloroMethyl)-2,5-diphenyloxazole
• Synonyms: 4-(ChloroMethyl)-2,5-diphenyloxazole
• CAS NO: 2549-33-9
• Molecular Formula: C₁₆H₁₂ClNO
• Molecular Weight: 269.72558
• Mol File: 2549-33-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 139 °C
• Boiling Point: 451.8±47.0 °C(Predicted)
• Appearance: /
• Density: 1.205±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 0.00±0.10(Predicted)
• CAS DataBase Reference: 4-(ChloroMethyl)-2,5-diphenyloxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(ChloroMethyl)-2,5-diphenyloxazole(2549-33-9)
• EPA Substance Registry System: 4-(ChloroMethyl)-2,5-diphenyloxazole(2549-33-9)

Safety Data

• Hazardous Substances Data: 2549-33-9(Hazardous Substances Data)

Upstream product

• 2549-30-6 4-Methyl-2,5-diphenyloxazole N-oxide 
• 119-51-7 1-phenyl-1,2-propanedione 2-oxime 
• 17019-26-0 (E)-2-(hydroxyimino)-1-phenylpropan-1-one 
• 100-52-7 benzaldehyde 

Downstream Products

• 2549-34-0 1-(2,5-diphenyl-oxazol-4-ylmethyl)-piperidine 
• 2549-38-4 4-(2,5-diphenyl-oxazol-4-ylmethyl)-morpholine 
• 2549-35-1 2,5-diphenyl-4-hydroxymethyloxazole 
• 2549-37-3 (2,5-diphenyl-oxazol-4-yl)-methanethiol 
• 144762-97-0 4-(4-Triphenylphosphoranylidene-3-butanon)-2,5-diphenyloxazole 
• 144936-85-6 (E)-6-{2-[2-(2,5-Diphenyl-oxazol-4-yl)-ethyl]-[1,3]dioxolan-2-yl}-hex-5-en-2-ol 
• 144763-00-8 4-(3-Dioxolan-8-hydroxy-5-E-nonen)-2,5-diphenyloxazole 
• 144993-60-2 N,N-Dibenzoyl-4-dioxolan-9-hydroxy-6-E-decenamide 
• 144936-88-9 4-<3-Oxo-8-(2',2',2'-trichloroethylcarbonoyl)-4-E-nonen>-2,5-diphenyloxazole 
• 144993-59-9 4-<3-Dioxolan-8-(2',2',2'-trichloroethylcarbonoyl)-5-E-nonen>-2,5-diphenyloxazole 
• 144936-84-5 Carbonic acid (E)-5-{2-[2-(2,5-diphenyl-oxazol-4-yl)-ethyl]-[1,3]dioxolan-2-yl}-1-methyl-pent-4-enyl ester 2,2,2-trichloro-ethyl ester 
• 24248-61-1 2-(2,5-diphenyloxazol-4-yl)acetonitrile 

Relevant articles and documents

PDE10 MODULATORS

The present invention relates to compounds of formula (I) wherein R1, R2, R3, R5, W, X, X1, Y, Y1, Z and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used in the treatment of CNS disorders such as schizophrenia, Alzheimer's disease, and Parkinson's disease.

The Singlet Oxygen Conversion of Oxazoles to Triamides. Application in the Synthesis of (+/-)-Pyrenolide C. Assignment of Stereochemistry.

Pyrenolide C has been synthesized for the first time using an oxazole template to construct the framework of the ten-membered unsaturated lactone system.The stereochemical assignment of the allylic alcohol substituent, based on the mode of synthesis, has